Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: From pilot to level 1 evidence studies

Clinical Chemistry

Volumn 48, Issue 8, 2002, Pages 1194-1197

  Duffy, Michael J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR MARKER; UROKINASE;

BREAST CANCER; CANCER INVASION; ENDOMETRIUM CANCER; HUMAN; METASTASIS; OVARY CANCER; PROGNOSIS; REVIEW; STOMACH CANCER;

EID: 0036329424     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/48.8.1194     Document Type: Review

References (25)

1. Angiogenesis and tumor metastasis
2. The urokinase-type plasminogen activator system in cancer metastasis: A review
3. Urokinase-generated plasmin activates matrix metalloproteinase during aneurysm formation
4. Plasminogen activator inhibitors: Hormonally regulated serpins
5. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin
6. Regulation of cell adhesion by PAI
7. The biochemistry of metastasis
8. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells
9. Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas
10. Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type-1 in an athymic mouse model
11. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells
12. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
13. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signalling and thereby promotes MCF-7 cell growth
14. Do proteases play a role in cancer invasion and metastasis?
15. Urokinase-plasminogen activator, a marker for aggressive breast cancer. Preliminary report
16. Urokinase plasminogen activator: A prognostic marker in multiple types of cancer
17. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy
18. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and their type 1 inhibitor in breast cancer
19. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers
20. Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 Workshop
21. External quality assessment of trans-European multicenter antigen determination (enzyme-linked immunosorbent assay) of urokinase plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) in human breast cancer extracts
22. Randomized adjuvant chemotherapy trial in high-risk node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1
23. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients
24. Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer
25. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualised therapy decisions in primary breast cancer is greatest when used in combination